ArticleInternational journal of clinical oncology2026
Nationwide genomic data analysis of central nervous system tumors in Japan based on C-CAT database.
Article in International journal of clinical oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundComprehensive genomic profiling test (CGPT) using next-generation sequencing (NGS) plays a vital role in cancer diagnosis, treatment option, and prognostic evaluation. In Japan, three tissue-based CGPTs, FoundationOne® CDx, GenMineTOP, and NCC OncoGuide™, are reimbursed under public health insurance. However, their comparative performance in central nervous system (CNS) tumors remains unclear.
methodsWe conducted a nationwide, retrospective analysis using data from the Center for Cancer Genomics and Advanced Therapeutics database. A total of 1,151 patients with CNS tumors who underwent CGPT between August 2023 and April 2025 were included. Patient characteristics, genetic mutations, tumor mutation burden, and numbers of drug and clinical trial suggestions were compared across the three CGPTs.
resultsFoundationOne® CDx detected significantly more mutations and copy number alterations than GenMineTOP and NCC OncoGuide. It also proposed more off-label drugs and domestic clinical trials. Conversely, GenMineTOP demonstrated the highest detection rate of gene fusions (9.6%), including KIAA1549-BRAF, FGFR3-TACC3, and EGFR-SEPT14, and PTPRZ1-MET. Furthermore, GenMineTOP identified germline mutations in 4.6% of patients, commonly involving TP53, BRCA2, and MSH6.
conclusionFoundationOne® CDx exhibits greater number of mutations, copy number alterations, and generating therapeutic suggestions, while GenMineTOP excels in identifying fusion genes and germline variants. These findings underscore that each CGPT possesses distinct analytical strengths, and the choice of platform may influence the genomic landscape and therapeutic opportunities identified in CNS tumor patients.
Indexed as
Identifiers
42089945What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.